Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-4.05%		-9.27%	-26.42%

Apr. 23	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	MT
Apr. 23	Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	CI

Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 15, 2023 at 04:32 pm EDT

Unity Biotechnology, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 59.93 million compared to USD 60.73 million a year ago. Basic loss per share from continuing operations was USD 6.31 compared to USD 10.88 a year ago.

Diluted loss per share from continuing operations was USD 6.31 compared to USD 10.88 a year ago.

Latest news about Unity Biotechnology, Inc.

Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	Apr. 23	MT
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	Apr. 23	CI
HC Wainwright Adjusts Unity Biotechnology Price Target to $8 From $10, Maintains Buy Rating	Apr. 16	MT
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 15	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	Feb. 06	CI
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	Dec. 12	CI
North American Morning Briefing : Stocks Futures -2-	Nov. 20	DJ
Wedbush Upgrades Unity Biotechnology to Outperform From Neutral, Says Remains in Execution Mode With Advancement of UBX1325; Raises PT to $4 From $2	Nov. 16	MT
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Sector Update: Health Care Stocks Rising Late Afternoon	Nov. 10	MT
Sector Update: Health Care	Nov. 10	MT
Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds; Shares Fall	Nov. 10	MT
UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	23-09-27	CI
Unity Biotechnology, Inc. enters into A Loan and Security Agreement	23-09-06	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
North American Morning Briefing : Stock Futures -2-	23-06-27	DJ
Wedbush Downgrades Unity Biotechnology to Neutral From Outperform, Notes Limited Cash Runway, Lack of Other Near-Term Value-Driving Catalysts; Trims PT to $2 From $3	23-06-26	MT
Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema	23-06-21	CI
Roth MKM Initiates Unity Biotechnology at Buy With $10 Price Target	23-05-31	MT
Citigroup Adjusts Price Target on Unity Biotechnology to $6 From $5, Maintains Buy Rating	23-05-26	MT
Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Wedbush Trims Unity Biotechnology's Price Target to $3 From $5 After Model Adjustments, Keeps Outperform Rating	23-04-25	MT

Chart Unity Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an Î±-Klotho hormone drug candidate, which is being researched for multiple neurology indications.

Sector

Biotechnology & Medical Research

Calendar

2024-06-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.42 USD

Average target price

6 USD

Spread / Average Target

+322.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
UNITY BIOTECHNOLOGY, INC.	-26.42%	23.84M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-3.52%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-6.50%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs